DE69320975D1 - Verwendung von (-) Cetirizin zur Behandlung allergischer Rhinitis und und Asthma - Google Patents

Verwendung von (-) Cetirizin zur Behandlung allergischer Rhinitis und und Asthma

Info

Publication number
DE69320975D1
DE69320975D1 DE69320975T DE69320975T DE69320975D1 DE 69320975 D1 DE69320975 D1 DE 69320975D1 DE 69320975 T DE69320975 T DE 69320975T DE 69320975 T DE69320975 T DE 69320975T DE 69320975 D1 DE69320975 D1 DE 69320975D1
Authority
DE
Germany
Prior art keywords
cetirizine
treatment
allergic rhinitis
asthma
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69320975T
Other languages
English (en)
Other versions
DE69320975T2 (de
Inventor
Nancy M Gray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25491375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69320975(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of DE69320975D1 publication Critical patent/DE69320975D1/de
Publication of DE69320975T2 publication Critical patent/DE69320975T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DE69320975T 1992-09-24 1993-09-22 Verwendung von (-) Cetirizin zur Behandlung allergischer Rhinitis und und Asthma Expired - Lifetime DE69320975T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95117992A 1992-09-24 1992-09-24
PCT/US1993/008991 WO1994006429A1 (en) 1992-09-24 1993-09-22 Compositions for treating allergic disorders using (-) cetirizine

Publications (2)

Publication Number Publication Date
DE69320975D1 true DE69320975D1 (de) 1998-10-15
DE69320975T2 DE69320975T2 (de) 1999-05-12

Family

ID=25491375

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2001199031 Active DE10199031I2 (de) 1992-09-24 1993-09-22 Verwendung von (-) Cetrizin zur Behandlung allergischer Rhinitis und Asthma.
DE69320975T Expired - Lifetime DE69320975T2 (de) 1992-09-24 1993-09-22 Verwendung von (-) Cetirizin zur Behandlung allergischer Rhinitis und und Asthma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE2001199031 Active DE10199031I2 (de) 1992-09-24 1993-09-22 Verwendung von (-) Cetrizin zur Behandlung allergischer Rhinitis und Asthma.

Country Status (12)

Country Link
US (1) US5698558A (de)
EP (2) EP0950412A3 (de)
JP (2) JPH08501561A (de)
AT (1) ATE170749T1 (de)
AU (2) AU4932093A (de)
CA (1) CA2145410A1 (de)
DE (2) DE10199031I2 (de)
DK (1) DK0663828T3 (de)
ES (1) ES2122042T3 (de)
LU (1) LU90898I2 (de)
NL (1) NL300085I2 (de)
WO (1) WO1994006429A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0885611A3 (de) * 1992-09-24 1999-01-07 Sepracor, Inc. Verfahren und Zusammensetzungen zur Behandlung von allergischen Krankheiten unter Verwendung von optisch reinen (+) Cetirizin
WO1994006429A1 (en) * 1992-09-24 1994-03-31 Sepracor, Inc. Compositions for treating allergic disorders using (-) cetirizine
GB9305282D0 (en) * 1993-03-15 1993-05-05 Ucb Sa Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine
US6469009B1 (en) 1996-04-08 2002-10-22 Ucb, S.A. Pharmaceutical compositions for the treatment of rhinitis
BE1011251A3 (fr) † 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
US6140337A (en) * 1997-12-23 2000-10-31 Schering Corporation Methods for the treatment of mental disorders
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
SE9802555D0 (sv) * 1998-07-16 1998-07-16 A & Science Invest Ab New pharmaceutical preparation and method
US6432961B1 (en) * 1998-08-18 2002-08-13 Ucb S.A. Method for preventing the onset of asthma
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
WO2002067938A2 (en) * 2000-10-30 2002-09-06 Schering Corporation Treating or reducing the risk of cardiovascular disease
US7199241B1 (en) 2001-05-29 2007-04-03 Ucb, S.A. Process for preparing (S) and (R)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide
US6977301B1 (en) 2001-05-29 2005-12-20 Ucb, S.A. Process for preparing (S) and (R)—2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide
US20040053902A1 (en) * 2002-09-13 2004-03-18 Smith C. Steven Novel composition and method for treatment of upper respiratory conditions
MXPA05005795A (es) * 2002-12-03 2005-08-16 Ucb Farchim Sa Uso de levocetiricina para el tratamiento de la rinitis alergica persistente.
AU2003228011A1 (en) * 2003-05-21 2004-12-13 Wockhardt Limited 2-(2-(4-((4-chlorophenyl) phenylmethyl)-1-piperazinyl)ethoxy)acetic acid monohydrochloride as anti-allergenic compound and process for its production
GB2403655A (en) * 2003-07-11 2005-01-12 Cipla Ltd Combined pharmaceutical product comprising a beta-2 adrenoreceptor agonist & an antihistamine for treatment of respiratory diseases such as asthma
WO2005041969A1 (en) * 2003-10-22 2005-05-12 Cipla Limited Pharmaceutical product comprising a beta-2 adrenergic agonist and an h1-receptor antagonist
WO2005077371A1 (en) * 2004-02-12 2005-08-25 Ucb Farchim Sa Use of levocetirizine for the preparation of a drug
CA2599498C (en) * 2005-03-03 2011-06-21 Ucb Farchim Sa Pyroglutamate salts and their use in the optical resolution of intermediates for the synthesis of dextrocetirizine and levocetirizine
US20090082364A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched levocedtirizine
JP5291324B2 (ja) * 2007-11-01 2013-09-18 沢井製薬株式会社 口腔内崩壊錠
DE602007012725D1 (de) 2007-11-21 2011-04-07 Synthon Bv Verfahren zur Herstellung von N-(Diphenylmethyl)piperazinen
US7989623B2 (en) 2007-11-21 2011-08-02 Synthon Bv Process for making n-(diphenylmethyl)piperazines
US20100145049A1 (en) * 2008-11-21 2010-06-10 Jie Zhu Process for making n-(diphenylmethyl)piperazines
WO2010107404A1 (en) 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
ES2910374T3 (es) 2009-03-17 2022-05-12 Nicox Ophthalmics Inc Formulaciones oftálmicas de cetirizina y procedimientos de uso
US8263581B2 (en) * 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
TR201007652A2 (tr) 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Sinerjik etki.
TR201009398A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Fiziksel özellikleri geliştirilmiş tablet formülasyonları
KR20130009553A (ko) * 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
KR102110304B1 (ko) 2017-06-30 2020-05-14 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성 및 복약순응도가 향상된 복합 츄어블정 및 그 제조방법
EP4321156A1 (de) 2021-10-21 2024-02-14 Han Wha Pharma Co., Ltd. Filmtablette mit verbesserter stabilität mit montelukast oder pharmazeutisch unbedenklichem salz davon und levocetirizin oder pharmazeutisch unbedenklichem salz davon

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155805C (no) * 1981-02-06 1987-06-10 Ucb Sa Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(4-(difenylmethyl)-1-piperazinyl)-eddiksyrer og deres amider og ikke-toksiske salter.
GB8827391D0 (en) * 1988-11-23 1988-12-29 Ucb Sa Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride
GB8827390D0 (en) * 1988-11-23 1988-12-29 Ucb Sa Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride
DE4209649C2 (de) * 1992-03-25 1998-12-24 Schloemann Siemag Ag Mehrstufiger hydraulischer Druck-Zylinder
WO1994006429A1 (en) * 1992-09-24 1994-03-31 Sepracor, Inc. Compositions for treating allergic disorders using (-) cetirizine
EP0885611A3 (de) * 1992-09-24 1999-01-07 Sepracor, Inc. Verfahren und Zusammensetzungen zur Behandlung von allergischen Krankheiten unter Verwendung von optisch reinen (+) Cetirizin
GB9305282D0 (en) * 1993-03-15 1993-05-05 Ucb Sa Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine

Also Published As

Publication number Publication date
DE10199031I1 (de) 2001-10-04
DE69320975T2 (de) 1999-05-12
EP0663828A1 (de) 1995-07-26
LU90898I2 (en) 2002-04-08
JP2006036791A (ja) 2006-02-09
AU4932093A (en) 1994-04-12
AU711212B2 (en) 1999-10-07
EP0950412A3 (de) 2001-05-16
DK0663828T3 (da) 1999-06-07
EP0663828B1 (de) 1998-09-09
JPH08501561A (ja) 1996-02-20
WO1994006429A1 (en) 1994-03-31
US5698558A (en) 1997-12-16
NL300085I1 (nl) 2002-05-01
AU5934398A (en) 1998-05-21
NL300085I2 (nl) 2002-06-03
CA2145410A1 (en) 1994-03-31
DE10199031I2 (de) 2004-09-23
ATE170749T1 (de) 1998-09-15
ES2122042T3 (es) 1998-12-16
EP0950412A2 (de) 1999-10-20

Similar Documents

Publication Publication Date Title
DE69320975D1 (de) Verwendung von (-) Cetirizin zur Behandlung allergischer Rhinitis und und Asthma
ATE177636T1 (de) Transdermale behandlung der nesselsucht mit optisch reinem (+)-cetirizin
BG103725A (en) Nicotineamide derivatives
ATE342964T1 (de) Rekombinante alpha-l-iduronisase, deren herstellungs- und aufreinigungsverfahren, und behandlung von durch diese hervorgerufene mangelerkrankungen
ES2171543T3 (es) Composiciones administrables topicamente que contienen derivados del acido 3-benzoilfenilacetico para el tratamiento de trastornos inflamatorios oftalmicos.
ATE274345T1 (de) Verfahren zur herstellung einer stabilen mikronisierten zusammensetzung von formoterol mit einem glucocorticosteroid
ATE168007T1 (de) Zur behandlung von erkrankungen des zentralnervensystems verwendbare benzimidazole
DE69030632D1 (de) Substituierte Chinolincarboxylsäure
PT87294A (pt) Process for the preparation of 17beta-(cyclopropylamino)-androst-5-en-3beta-ol and related compounds useful as c17-20 lyase inhibitors and of pharmaceutical compositions containing the same
ATE366116T1 (de) Verwendung von alpha-msh und epo zur herstellung eines arzneimittels zur prophylaxe oder behandlung von durch ischämischen zuständen bewirkten krankheiten
ATE101147T1 (de) Pharmazeutisch verwendbare polymorphe modifikation von buspiron.
ATE269705T1 (de) Verwendung von optisch reinem (r)-tofizopam zur behandlung und pravention von angststörungen
IS3961A (is) Indolafleiður, aðferð til framleiðslu þeirra og notkunar sem lyfja
ATE83480T1 (de) Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
DE3773059D1 (de) Ester von salsalat mit guajakol zur behandlung von phlogistischen bronchopneumopathien.
DE60107516D1 (de) Verwendung von Pregabalin zur Asthma Behandlung
FR2653999B1 (de)
FI851617L (fi) Triazolopyrimidinderivat.
DE502004011353D1 (de) Verfahren zur Destillation eines Gemisches isomerer Diisocyanatodiphenylmethane
PT77880B (de) Neue 6alpha-methylprednisolon-derivate ihre herstellung und verwendung

Legal Events

Date Code Title Description
V448 Application of spc
V484 Delivery of the decision of grant
V457 Spc granted
V460 Request of annulation for spc